Related Experiment Video

Updated: Aug 23, 2026

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
11:36

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs

Published on: April 21, 2012

Azithromycin in the treatment of mucosal leishmaniasis

Mario León Silva-Vergara1, Luciana de Almeida Silva, Frederico Ricardo Zago Maneira

  • 1Departamento de Clínica Médica, Faculdade de Medicina do Triângulo Mineiro, Uberaba, MG, Brazil. dip_fmtm@mednet.com.br

Revista Do Instituto De Medicina Tropical De Sao Paulo
|August 3, 2004
PubMed

Insights

Azithromycin effectively healed leishmaniasis lesions in elderly patients with heart conditions. This antibiotic offers a safe alternative treatment for leishmaniasis, especially when traditional drugs are not suitable.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Tropical Medicine

Background:

  • American tegumentary leishmaniasis (ATL) is a significant public health concern.
  • Traditional treatments for leishmaniasis carry risks of toxicity, particularly in elderly patients or those with comorbidities.
  • Alternative therapeutic options with improved safety profiles are needed for ATL management.

Observation:

  • Three elderly patients with mucosal ATL and chronic cardiopathy were treated.
  • Patients received oral azithromycin (500 mg daily for 10 days) every other month for three courses.
  • Lesions healed completely in all patients after the third treatment course.

Findings:

  • Azithromycin demonstrated high efficacy in healing mucosal leishmaniasis lesions.
  • One patient experienced a relapse, successfully treated with an additional azithromycin course.
  • The drug was well-tolerated, with no significant adverse events reported.

Implications:

  • Azithromycin presents a promising alternative for treating leishmaniasis in specific patient populations.
  • Its oral administration, single daily dosage, and favorable safety profile make it suitable for patients with contraindications to standard therapies.
  • Further research is warranted to elucidate the precise mechanism of azithromycin against Leishmania species.

More Related Videos

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line12:22

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line

Published on: December 30, 2012

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity12:02

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity

Published on: November 2, 2016

Related Concept Videos

Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Leishmaniasis01:30

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
Trichomoniasis01:18

Trichomoniasis

Trichomonas vaginalis is a flagellated protozoan parasite and the causative agent of trichomoniasis, one of the most prevalent non-viral sexually transmitted infections in the United States. This extracellular parasite primarily colonizes the lower genitourinary tract in women—particularly the vagina—and in men, the urethra and prostate. Its structural and functional adaptations enable its survival, motility, and pathogenicity within the host environment.Structural Features and Host EntryT.
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.